Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Oncology and fibrosis focused Redx Pharma reported a deeper annual loss after rising revenue was offset by higher spending on its development pipeline.
Pre-tax losses for the year through September amounted to £9.2 million, compared to year-on-year losses of £6.3 million.
Revenue rose to £5.7 million, up from £3.1 million.
'Despite clinical development challenges that have affected us, as well as many other companies in our sector, as a result of the global Covid-19 pandemic, Redx has managed to progress its pipeline, further developing its lead programmes in oncology and fibrosis, and is on track to deliver on key milestones in 2021,' chairman Iain Ross said.
'We have a strong and talented management and scientific team and it is with this expertise that Redx has continued to grow and move forward with its strategy.'
At 8:52am: (LON:REDX) Redx Pharma Plc share price was 0p at 62.5p